Targeting targeted agents: Open issues for clinical trial design

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Bria, Emilio ^a   Di Maio, Massimo ^b   Carlini, Paolo ^a   Cuppone, Federica ^a   Giannarelli, Diana ^a   Cognetti, Francesco ^a   Milella, Michele ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; PLACEBO; SORAFENIB; SUNITINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; GENE TARGETING; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MEDICAL PRACTICE; METHODOLOGY; MONOTHERAPY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; CLINICAL TRIAL; DRUG DESIGN; NEOPLASM;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 67949117222     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-66     Document Type: Review

References (34)

1. Erlotinib in previously treated non-small-cell lung cancer. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins M van Kooten M Dediu B Findlay D Tu D Johnston A Bezjak G Clark P Santabarbara L Seymour, N Engl J Med 2005 353 123 132 10.1056/NEJMoa050753 16014882 (Pubitemid 41058344)
2. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger HJ Au P Murawa D Walde RA Wolff D Campos R Lim K Ding G Clark T Voskoglou-Nomikos M Ptasynski W Parulekar, J Clin Oncol 2007 25 1960 1966 10.1200/JCO.2006.07.9525 17452677 (Pubitemid 46972777)
3. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). N Thatcher A Chang P Parikh J Rodrigues Pereira T Ciuleanu J von Pawel S Thongprasert EH Tan K Pemberton V Archer K Carroll, Lancet 2005 366 1527 1537 10.1016/S0140-6736(05)67625-8 16257339 (Pubitemid 41540110)
4. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. K Kelly K Chansky LE Gaspar KS Albain J Jett YC Ung DH Lau JJ Crowley DR Gandara, J Clin Oncol 2008 26 2450 2456 10.1200/JCO.2007.14.4824 18378568
5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson, N Engl J Med 2007 357 2666 2676 10.1056/NEJMoa072113 18160686
6. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton, N Engl J Med 2001 344 783 792 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
7. Evaluating the efficiency of targeted designs for randomized clinical trials. R Simon A Maitournam, Clin Cancer Res 2004 10 6759 6763 10.1158/1078-0432.CCR-04-0496 15501951 (Pubitemid 39383023)
8. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. BP Schneider M Wang M Radovich GW Sledge S Badve A Thor DA Flockhart B Hancock N Davidson J Gralow M Dickler EA Perez M Cobleigh T Shenkier S Edgerton KD Miller, J Clin Oncol 2008 26 4672 4678 10.1200/JCO.2008.16.1612 18824714
9. Methodology of clinical trials with new molecular-targeted agents: where do we stand? A Morabito M Di Maio E De Maio N Normanno F Perrone, Ann Oncol 2006 17 Suppl 7 vii128 131 10.1093/annonc/mdl965 16760275 (Pubitemid 43985193)
10. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing. AJ Vickers V Ballen HI Scher, Clin Cancer Res 2007 13 972 976 17277252 10.1158/1078-0432.CCR-06-0909 (Pubitemid 46340375)
11. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. MJ Ratain TG Karrison, Clin Cancer Res 2007 13 781 782 10.1158/1078-0432.CCR-06-2533 17289865 (Pubitemid 46340347)
12. Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? JK Chan SM Ueda VE Sugiyama CD Stave JY Shin BJ Monk BI Sikic K Osann DS Kapp, J Clin Oncol 2008 26 1511 1518 10.1200/JCO.2007.14.8874 18285603
13. A quantitative analysis of kinase inhibitor selectivity. MW Karaman S Herrgard DK Treiber P Gallant CE Atteridge BT Campbell KW Chan P Ciceri MI Davis PT Edeen R Faraoni M Floyd JP Hunt DJ Lockhart ZV Milanov MJ Morrison G Pallares HK Patel S Pritchard LM Wodicka PP Zarrinkar, Nat Biotechnol 2008 26 127 132 10.1038/nbt1358 18183025
14. Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream. A Di Leo E Moretti, J Clin Oncol 2008 26 5011 5013 10.1200/JCO.2008.18.3137 18768431
15. Sorafenib in advanced hepatocellular carcinoma. JM Llovet S Ricci V Mazzaferro P Hilgard E Gane JF Blanc AC de Oliveira A Santoro JL Raoul A Forner M Schwartz C Porta S Zeuzem L Bolondi TF Greten PR Galle JF Seitz I Borbath D Haussinger T Giannaris M Shan M Moscovici D Voliotis J Bruix, N Engl J Med 2008 359 378 390 10.1056/NEJMoa0708857 18650514
16. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim I Chen PW Bycott CM Baum RA Figlin, N Engl J Med 2007 356 115 124 10.1056/NEJMoa065044 17215529 (Pubitemid 46089672)
17. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. B Freidlin R Simon, Clin Cancer Res 2005 11 7872 7878 10.1158/1078-0432.CCR-05-0605 16278411 (Pubitemid 41611633)
18. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). L Paz-Ares JM Sanchez A Garcia-Velasco B Massuti G Lopez-Vivanco M Provencio A Montes D Isla ML Amador R Rosell G Spanish Lung Cancer, J Clin Oncol (Meeting Abstracts) 2006 24 7020
19. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. RH El-Maraghi EA Eisenhauer, J Clin Oncol 2008 26 1346 1354 10.1200/JCO.2007.13.5913 18285606
20. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? MJ Ratain RH Glassman, Clin Cancer Res 2007 13 6545 6548 10.1158/1078-0432.CCR-07-2133 18006752 (Pubitemid 350206786)
21. Improving the design of phase II trials of cytostatic anticancer agents. A Stone C Wheeler A Barge, Contemp Clin Trials 2007 28 138 145 10.1016/j.cct.2006.05.009 16843736 (Pubitemid 44937880)
22. A comparative review of four preference-weighted measures of health-related quality of life. JA Kopec KD Willison, J Clin Epidemiol 2003 56 317 325 10.1016/S0895-4356(02)00609-1 12767408 (Pubitemid 36593310)
23. Randomized discontinuation design: application to cytostatic antineoplastic agents. GL Rosner W Stadler MJ Ratain, J Clin Oncol 2002 20 4478 4484 10.1200/JCO.2002.11.126 12431972 (Pubitemid 35334760)
24. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. CS Karapetis S Khambata-Ford DJ Jonker CJ O'Callaghan D Tu NC Tebbutt RJ Simes H Chalchal JD Shapiro S Robitaille TJ Price L Shepherd HJ Au C Langer MJ Moore JR Zalcberg, N Engl J Med 2008 359 1757 1765 10.1056/NEJMoa0804385 18946061
25. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. C Bokemeyer I Bondarenko JT Hartmann FG De Braud C Volovat J Nippgen C Stroh I Celik P Koralewski, J Clin Oncol (Meeting Abstracts) 2008 26 4000
26. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. E Van Cutsem I Lang G D'Haens V Moiseyenko J Zaluski G Folprecht S Tejpar O Kisker C Stroh P Rougier, J Clin Oncol (Meeting Abstracts) 2008 26 2
27. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. RG Amado M Wolf M Peeters E Van Cutsem S Siena DJ Freeman T Juan R Sikorski S Suggs R Radinsky SD Patterson DD Chang, J Clin Oncol 2008 26 1626 1634 10.1200/JCO.2007.14.7116 18316791
28. Influence of unrecognized molecular heterogeneity on randomized clinical trials. RA Betensky DN Louis JG Cairncross, J Clin Oncol 2002 20 2495 2499 10.1200/JCO.2002.06.140 12011127 (Pubitemid 34525735)
29. The challenge of subgroup analyses reporting without distorting. SW Lagakos, N Engl J Med 2006 354 1667 1669 10.1056/NEJMp068070 16625007
30. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. ST Brookes E Whitley TJ Peters PA Mulheran M Egger G Davey Smith, Health Technol Assess 2001 5 1 56 11701102
31. Statistics notes. Interaction 1: Heterogeneity of effects. DG Altman JN Matthews, Bmj 1996 313 486 8776324
32. Randomized phase III clinical trial designs for targeted agents. A Hoering M Leblanc JJ Crowley, Clin Cancer Res 2008 14 4358 4367 10.1158/1078-0432.CCR-08-0288 18628448
33. Statistical design considerations for pilot studies transitioning therapies from the bench to the bedside. RE Carter RF Woolson, J Transl Med 2004 2 37 15511289 10.1186/1479-5876-2-37 (Pubitemid 40617853)
34. Endothelin receptors as novel targets in tumor therapy. A Bagnato PG Natali, J Transl Med 2004 2 16 15165288 10.1186/1479-5876-2-16 (Pubitemid 39130356)